Amanda Stanford, APRN
Adult Health · Greenville, NCNPI 1558985036
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,572 of the $5,418 with a category attached, or 65.9%. 28 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 29.7% of the total. Reporting peaked in 2023 at $2,908 and has fallen 82.4% since, to $512 in 2025. Among adult health clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 75 payments — averaging $72.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$2K
- Bristol Myers Squibb$752
- AstraZeneca$335
- Incyte Corporation$261
- Seagen Inc.$248
- Rigel Pharmaceuticals, Inc.$233
- plus $2K from 22 others
What the payments were for
- Consulting fees$68113%
- Travel & lodging$1,06320%
- Food & beverage$3,57266%
- Education$1012%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 7 | $1,608 |
| Bristol Myers Squibb | 7 | $752 |
| AstraZeneca | 3 | $335 |
| Incyte Corporation | 3 | $261 |
| Seagen Inc. | 3 | $248 |
| Rigel Pharmaceuticals, Inc. | 3 | $233 |
| CTI Biopharma Corp. | 2 | $220 |
| Gilead | 2 | $180 |
| Merck | 7 | $156 |
| Sanofi Pasteur Inc. | 8 | $149 |
| Karyopharm Therapeutics Inc. | 2 | $136 |
| GSK | 2 | $120 |
| Vifor Pharma, Inc. | 1 | $120 |
| Agios Pharmaceuticals, Inc. | 1 | $119 |
| Amgen | 1 | $116 |
| Sobi, Inc | 1 | $110 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $77 |
| Pfizer | 4 | $75 |
| TG Therapeutics, Inc. | 1 | $74 |
| AbbVie | 4 | $73 |
| Novartis | 3 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $59 |
| Pharmacosmos Therapeutics Inc. | 2 | $39 |
| AVEO Pharmaceuticals, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Pharmaessentia USA Corporation | 1 | $16 |
| Geron Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,418 in reported general payments places this provider in the 90th percentile of 614 adult health providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 56 | $834,115 |
| ImbruvicaIbrutinib | 47 | $744,654 |
| VenclextaVenetoclax | 25 | $387,086 |
| CalquenceAcalabrutinib Maleate | 14 | $222,226 |
| EliquisApixaban | 27 | $15,585 |
| ValacyclovirValacyclovir Hcl | 81 | $4,446 |
| Imatinib Mesylate | 19 | $1,058 |
| Hydroxyurea | 31 | $884 |
| Olanzapine | 13 | $777 |
| Fluconazole | 14 | $444 |
| Potassium Chloride | 23 | $239 |
| Allopurinol | 30 | $176 |
| Anastrozole | 13 | $149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $77 | $744,65447 claims |
| AbbVieVenclexta | $73 | $387,08625 claims |
| AstraZenecaCalquence | $335 | $222,22614 claims |
| PfizerEliquis | $75 | $15,58527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 614 adult health providers in North Carolina.
Other adult health in Greenville
- Felicia RichardsonGreenville$64K
- Amy HopkinsGreenville$31K
- Lakeisha GreenfieldGreenville$15K
- Veronica PriceGreenville$10K
- Heather LarsenGreenville$9K
- Steffani LetchworthGreenville$8K
- Robert DodgeRaleigh$311K
- Kimberly CampDurham$147K
- Henry VanpalaRaleigh$110K
- Jolene SpencerWashington$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.